Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predicting Efficacy of Cetuximab and Bevacizumab in mCRC
NCT00327093Phase 4Terminated
- Sponsor
- Hospices Civils de Lyon
- Start
- May 2006
- Primary completion
- Oct 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of cetuximab and bevacizumab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Response to treatment according to RECIST criteria at 2 months. Started May 2006; status: terminated.
02
Drugs
cetuximabbevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00327093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00327093.